CD8A and congenital rubella syndrome: Similar results have been found for CAR-T cell therapy based on preclinical studies, with CD4 CAR-T cells needed in addition to CD8 CAR-T cells for maximal response29,31; however, CD4 CAR-T cells have been implicated in driving cytokine release syndrome (CRS)26–30.